Matinas BioPharma Holdings, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q2 2019 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Matinas BioPharma Holdings, Inc. annual/quarterly Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q2 2019 to Q1 2023.
  • Matinas BioPharma Holdings, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending March 31, 2023 was $1.1M.
  • Matinas BioPharma Holdings, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $1.1M, a 65.6% decline from 2022.
  • Matinas BioPharma Holdings, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $3.19M, a 9561% increase from 2021.
  • Matinas BioPharma Holdings, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $33K, a 79.2% decline from 2020.
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $1.1M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q3 2022 $1.06M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $1.06M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2021 $33.3K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q3 2020 $95.8K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2019 $89.8K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.